Experimental cancer drug trial halted early

NCT ID NCT05607199

Terminated Disease control Sponsor: Aurigene Discovery Technologies Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called AUR103 Calcium in 27 adults with advanced solid tumors, acute myeloid leukemia, myelodysplastic syndromes, or non-Hodgkin lymphoma who had no other treatment options. The goal was to find the best dose and check safety. The study was terminated early, so no final results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes neoplasm non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES NON-HODGKIN LYMPHOMA SOLID TUMOR, ADULT

Contacts and locations

Locations

All India Institute of Medical Sciences

Delhi, National Capital Territory of Delhi, 10029, India
Grant Medical Foundation Ruby Hall Clinic

Pune, Maharashtra, 411001, India
K R Hospital

Mysore, Karnataka, 570001, India
Kiran Multi Super Specialty Hospital

Surat, Gujarat, 395004, India
Unique Hospital

Surat, Gujarat, 395002, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.